Scarica l'app Stockscreener
0.88
60.89%
-1.37
Dopo l'orario di chiusura:
.86
-0.02
-2.27%
Precedente Chiudi:
$2.25
Aprire:
$0.7648
Volume 24 ore:
33.32M
Relative Volume:
17.35
Capitalizzazione di mercato:
$120.05M
Reddito:
-
Utile/perdita netta:
$-59.69M
Rapporto P/E:
-0.6331
EPS:
-1.39
Flusso di cassa netto:
$-46.54M
1 W Prestazione:
-53.68%
1M Prestazione:
-49.43%
6M Prestazione:
-42.48%
1 anno Prestazione:
-50.84%
Intervallo 1D:
$0.75
$1.32
Intervallo di 1 settimana:
$0.75
$2.36
Portata 52W:
$0.75
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Confronta MIST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
0.88 | 120.05M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance
Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView
Sector Update: Health Care - TradingView
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - Asianet Newsable
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters.com
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks
Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus.com
Milestone flagging following CRL - The Pharma Letter
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com
Milestone Pharma says FDA declined to approve heart disorder therapy - MSN
Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com
FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus.com
Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma
Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha
FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com
Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView
FDA flags issues with Milestone’s new drug application - Investing.com India
Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks
US FDA declines to approve Milestone's heart rhythm nasal spray - TradingView
FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com
Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - Marketscreener.com
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha
HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World
Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - The Manila Times
Breakthrough PSVT Treatment Data: Etripamil Proves Effective for Multiple Episodes - StockTitan
Jones Financial Companies Lllp Raises Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
HC Wainwright Has Negative Outlook of MIST FY2028 Earnings - Defense World
Milestone Pharmaceuticals sets annual meeting date - Investing.com
Milestone Pharmaceuticals sets annual meeting date By Investing.com - Investing.com UK
PDUFA Date Nearing for New PSVT Drug - Streetwise Reports
Milestone Pharma Expands Sale Agreement, Increases Offering By Investing.com - Investing.com Canada
SEC Form 424B5 filed by Milestone Pharmaceuticals Inc. - Quantisnow
Milestone Pharmaceuticals enters open market sale agreement with Jefferies -March 18, 2025 at 05:51 pm EDT - Marketscreener.com
Milestone Pharma Expands Sale Agreement, Increases Offering - Investing.com India
Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright - Defense World
Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects - TipRanks
Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength - TipRanks
Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates - Nasdaq
Milestone Pharmaceuticals Inc. SEC 10-K Report - TradingView
Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Thursday - Defense World
3 Reasons GNK is Risky and 1 Stock to Buy Instead - The Globe and Mail
Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments - CNBCTV18
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):